Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Valorada de forma justa
El PE más reciente de la empresa es -8.21, en un rango percentil medio de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 18.21M acciones, lo que supone una reducción del 7.22% con respecto al trimestre anterior.
En posesión de ETHSX
El inversor estrella ETHSX posee 46.95K acciones de este valor.
Menor actividad del mercado
La empresa está generando menos interés entre los inversores, con una relación de rotación de 20 días del %!.(string=-0.23)